Skip to main content
. 2020 Mar 6;6:8. doi: 10.1038/s41523-020-0151-5

Fig. 1. Comparison of the ER+/HER2− Basal subtype, ER+/HER2− Luminal subtype, and ER− Basal subtype breast cancers.

Fig. 1

a Kaplan−Meier postoperative DRFI curves in early BCs according to the ER IHC status and the 80-GS molecular type. b Similar to (a), but in ER+/HER2− early BCs patients only, untreated (dashed curves) and treated (solid curves) with adjuvant HT. c Heatmap of the odds ratios (ORs) of regression analysis between the three tumor subtypes (ER+/HER2− Luminal subtype, ER+/HER2− Basal subtype, and ER− Basal subtype used as reference for comparison) for different variables related to the percent of pCR after CT or the probability of therapeutic response of BC to CT, HT, CDK4/6 inhibitors, PIK3CA inhibitor, PARP inhibitors, and immune checkpoint inhibitors. Variables associated to mammary stem cells are also shown. For each variable, the ORs are mean-centered and color-coded according to the color scale shown below. On the right, the bar plots represent the log10-transformed q values of regression analysis for the comparison of each variable between ER+/HER2− Basal subtype versus ER+/HER2− Luminal subtype (blue bar), and between ER+/HER2− Basal subtype versus ER− Basal subtype (orange bar). The longer is the bar, the lower is the q value.